Study of Autologous PRP Intra-Ovarian Infusion to Restore Ovarian Function in Women Aged 45 to 55 with Menopause

What this Trial Is About

Researchers are evaluating the effectiveness of autologous platelet-rich plasma PRP intra ovarian infusion in menopausal women to restore ovarian function and support follicle growth. This trial focuses on women between 45 and 55 years old who have experienced menopause. PRP contains growth factors that may stimulate tissue regeneration, and this study aims to clarify its role in ovarian rejuvenation and hormonal improvement during menopause. Participants will receive either autologous PRP intra ovarian infusion or a placebo infusion of platelet-free plasma PFP. The study is a triple-blind randomized controlled trial comparing these two treatments to assess their effects on ovarian function. The treatment is given once, and participants are monitored over a three-month period following the infusion. During the study, participants will undergo monthly evaluations for three months to measure restoration of menstrual cycles and various hormone levels, including serum FSH, AMH, estradiol, LH, and progesterone. Antral follicle count will also be assessed as a secondary outcome. The study includes safety monitoring and adherence to protocol requirements, with participation lasting at least three months from treatment to follow-up assessments.

Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal Women